Source Fact: Financial Supervisory Service DART / 2026-05-08
Disclosure Type: Tentative Business Performance based on Consolidated Financial Statements (Fair Disclosure)
💡 3-Second Summary
Alteogen recorded KRW 71.6B in revenue and KRW 39.3B in operating profit for Q1 2026. While revenue rose 11.0% quarter-on-quarter (QoQ), operating profit achieved an explosive 100.1% growth compared to the previous quarter, demonstrating stellar profitability.
📊 1. [Key Disclosure Details & Figures Summary]
- Performance Period: January 1, 2026 ~ March 31, 2026 (Q1 2026)
- Revenue: KRW 71.599B (Approx. KRW 71.6B)
- Up 11.0% compared to the previous quarter (Q4 2025)
- Down 14.5% compared to the same period last year (Q1 2025)
- Operating Profit: KRW 39.301B (Approx. KRW 39.3B)
- Up 100.1% (Doubled) compared to the previous quarter (Q4 2025)
- Down 35.6% compared to the same period last year (Q1 2025)
- Net Profit: KRW 71.344B (Approx. KRW 71.3B)
- Down 4.1% compared to the previous quarter (Q4 2025)
- Down 14.1% compared to the same period last year (Q1 2025)
- Note: The company achieved an astonishing operating profit margin of 54.9%, highlighting the exceptionally low cost structure typical of high-value-added biotech platform providers.
📈 2. [Expert Insight: Stock Price Impact Analysis]
- Stellar Earnings Surprise on a QoQ Basis: While YoY figures show a decline due to the high base effect from Q1 2025, the critical takeaway is the 100.1% surge in operating profit compared to Q4 2025. This indicates a steady influx of technology milestones or highly optimized R&D expense management, effectively clearing any short-term market anxieties regarding profitability.
- Fundamental Strengths Evidenced by a 55% Margin: Unlike traditional manufacturing, Alteogen’s business model—centered around licensing out proprietary platform technologies—has fully matured. Since more than half of the top-line revenue triggers straight into operating profit, any future technology transfers or commercial royalty inflows will amplify net earnings exponentially.
- Upward Momentum for Stock Price: Providing early visibility into robust earning power through this tentative disclosure will significantly bolster valuation confidence among institutional and foreign investors. It forms a solid downside cushion and reinforces Alteogen’s leadership position in the biotech sector, paving the way for a highly positive stock performance.
📝 Editor’s Comment (by K-STOCK Editor)
A mind-blowing ‘100% QoQ surge’ in operating profit is officially locked in! The stereotype that biotech companies only burn through cash for R&D is completely shattered. Out of KRW 71.6B in revenue, a whopping KRW 39.3B was retained as operating profit. With an incredible 55% margin, Alteogen has single-handedly justified why it commands the top-tier crown in the Kosdaq market. Investors fixated only on YoY declines are completely missing out on this vertical acceleration in sheer profitability. Backed by solid cash inflows, Alteogen’s rally now has the ultimate fundamental engine!
📢 Disclaimer & Source Information
Source: This content was structured and generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!